(Q46921577)

26 December 2017

title

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli (English)

1 reference

26 December 2017

main subject

Gram-negative bacteria

0 references

1 reference

1 reference

1 reference

Leonardo Lorente

1

1 reference

26 December 2017

Lisset Lorenzo

2

1 reference

26 December 2017

María M Martín

3

1 reference

26 December 2017

Alejandro Jiménez

4

1 reference

26 December 2017

María L Mora

5

1 reference

26 December 2017

language of work or name

English

0 references

publication date

31 January 2006

1 reference

26 December 2017

Annals of Pharmacotherapy

published in

1 reference

26 December 2017

volume

40

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

page(s)

219-223

1 reference

26 December 2017

Hospital-acquired pneumonia. Attributable mortality and morbidity

cites work

1 reference

Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay

21 January 2018

1 reference

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

21 January 2018

1 reference

Role of pharmacokinetics in the outcome of infections

21 January 2018

1 reference

Continuous infusion of beta-lactam antibiotics

21 January 2018

1 reference

Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance

21 January 2018

1 reference

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

21 January 2018

1 reference

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

21 January 2018

1 reference

Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

21 January 2018

1 reference

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

21 January 2018

1 reference

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

21 January 2018

1 reference

Continuous infusion versus intermittent administration of meropenem in critically ill patients

21 January 2018

1 reference

Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection

21 January 2018

1 reference

Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections

21 January 2018

1 reference

Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy

21 January 2018

1 reference

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

21 January 2018

1 reference

Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group

21 January 2018

1 reference

The effect of late-onset ventilator-associated pneumonia in determining patient mortality

21 January 2018

1 reference

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

Appropriate antimicrobial treatment in nosocomial infections—the clinical challenges

21 January 2018

1 reference

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

21 January 2018

1 reference

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G467

1 reference

26 December 2017

PubMed ID

16449546

1 reference

26 December 2017